CHMP extensions for Roche's Tarceva, Novartis' Afinitor and Wyeth's Enbrel
This article was originally published in Scrip
Following its meeting on 21st July 2011, the Committee for Medicinal Products for Human Use (CHMP), advisers to the European Commission, gave a positive opinion on the use of Roche's Tarceva (erlotinib) as a first-line treatment in locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. The opinion, which was made public on 22 July, makes it clear that the CHMP believes that the drug has not demonstrated benefit in EGFR-negative tumours.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.